Application of microRNA in preparation of medicaments for treating prostatic cancer

A prostate cancer and prostate technology, applied in gene therapy, drug combination, anti-tumor drugs, etc.

Inactive Publication Date: 2015-11-18
CHINA AGRI UNIV
View PDF5 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Dysregulation of miRNA expression in cells can lead to the occurrence of various diseases including cancer. The latest research shows that some miRNAs are abnormally expressed in prostate, but there is still no consensus on which miRNA is related to the occurrence and development of prostate cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of microRNA in preparation of medicaments for treating prostatic cancer
  • Application of microRNA in preparation of medicaments for treating prostatic cancer
  • Application of microRNA in preparation of medicaments for treating prostatic cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] The cell PC-3 used in the examples was purchased from ATCC, the American Type Culture Collection, the transfection reagent lipofectamine2000 was purchased from invitrogen, miR-487mimic was purchased from Life Technologies Corporation (product ID number is MC10648), and miR-487inhibitor was purchased from Life Technologies Corporation (product ID number is MH10648).

[0040] This example demonstrates the inhibitory effect of miR-487 on the metastasis of prostate tumor cells through in vitro cell biology experiments.

[0041] The PC-3 cell line was cultured, divided into experimental group and control group, transfected with miR-NC (negative control) and miR-487, respectively, and the changes of cell proliferation, migration and apoptosis were detected.

[0042] (1) miR-487 can inhibit cell proliferation and clone into spheres:

[0043] The miR-487mimics of miR-487 were transfected with lipofectamine2000 (transfected directly with transfection reagent lipofectamine2000) ...

Embodiment 2

[0052] This example demonstrates the inhibitory effect of miR-487 on the metastasis of prostate tumor cells through in vivo experiments.

[0053] Ten nude mice were randomly divided into two groups, and the control group was injected with PC-3M-luc expressing control miRNA (the cells were obtained by transfecting PC-3 cells derived from ATCC with a luciferase reporter vector) into the tail vein. The number of cells is 6×10 6 ; The experimental group was injected with the PC-3M-luc cell line expressing miR-487, and the number of cells was 6×10 6 ; 5 weeks after cell injection, each mouse was injected with 100 μl of luciferase substrate D-luciferin at a concentration of 30 μg / μl every week, and then the distribution of luciferase was observed by live imaging of small animals, and the metastasis rate of cancer cells was counted for three consecutive weeks. After the PC-3 cell line was transfected with miR-NC and miR-487, the changes of cell migration were detected by transwell m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of microRNA in the preparation of medicaments for treating prostatic cancer and relates to a pharmaceutical composition using miR-487 as an active component. The pharmaceutical composition is capable of inhibiting a development process of the prostatic cancer through the inhibitory action of the miR-487 upon transferability of prostatic cancer cells, with inhibitory efficiency up to 80%.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to the application of microRNA in the preparation of drugs for treating prostate cancer. Background technique [0002] Prostate cancer is the most common malignant tumor in male reproduction, and its incidence increases with age. It is second only to lung cancer and is the second leading cause of cancer death in men. In 2009, there were an estimated 192,280 new cases and 27,360 deaths from prostate cancer in the United States. Due to the aging population in my country, the incidence of prostate cancer has increased. Clinically, surgery or radiotherapy is effective for localized prostate cancer, but it is incurable for metastatic prostate cancer, and there is still a lack of effective drugs for the treatment of metastatic prostate cancer. miRNA is an endogenous non-coding small molecule RNA that regulates gene expression. It regulates gene expression at the post-transcriptional level a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K31/7105A61K45/00A61K31/282A61K33/24A61P35/00A61P35/04
Inventor 李向东于万鹏
Owner CHINA AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap